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Abstract
In humans, members of the RAS gene family are mutated in many cancers. There 
are three homologous RAS genes: HRAS, NRAS, and KRAS. These genes are greater than 
90% identical in amino acid sequence. However, KRAS has a rare codon bias while HRAS 
and NRAS feature common codons. Interestingly, KRAS is mutated far more frequently in 
human cancers than either HRAS or NRAS. Therefore, identifying genes regulating codon 
biased mRNAs or proteins could provide insights into how KRAS functions as a potent 
oncogene. In order to identify these genes, I took part in a deficiency screen in 
Drosophila. By driving either rare or common RAS constructs in the eye, can identify 
deficiencies that differentially modify the eye tumor phenotype, eventually identifying 
specific genes. We have currently identified deficiencies that differentially modify the 
common and rare phenotypes, showing that our model works. Following up on our 
screen, I have identified Ribosomal Protein S21 as a key gene within a modifying 
deficiency as our first candidate regulator of RAS codon bias.
Introduction
Codons, which code for amino acids when translating mRNA into protein, are 
each made up of three nitrogenous bases. Because there are 64 possible codon 
combinations and only 20 amino acids from which all proteins are synthesized, there is 
an inherent redundancy in the genetic code; multiple codons can code for the same amino 
acid. However, not every codon is equally used. It has been observed that many species, 
including Drosophila, have naturally occurring codon-usage bias, in which specific 
codons are over represented or completely avoided in the genome or in specific gene 
families (Kudla and Plotkin 2010). Common codons are those that are found most 
frequently in the genome of the organism, while the of rare codons are used much less 
frequently.
When a point mutation occurs such that it changes a gene’s sequence without 
altering the amino acid sequence of the final protein it is called a synonymous mutation. 
These mutations alter codons, but because of the redundancy in the genetic code the 
codon will still code for the same amino acid. Previously, it was thought that because 
these mutations were synonymous, they would have no effect on the protein or organism. 
However, recently it has been shown that in fact, these synonymous mutations can 
sometimes have adverse effects, and can even be the driver mutations in certain cancers 
(Supek et al. 2014). Outside of cancer, it has been shown that codon bias affects circadian 
rhythm (Xu et al. 2013, Zhou et al. 2013) and can determine the mutability and 
evolutionary capacity for viruses (Lauring et al. 2012). Clearly, codon bias can have 
diverse effects that are only beginning to be understood.
Members of the RAS gene family are proto oncogenes that are mutated in many 
cancers. RAS is an intracellular GTPase that resides at the cell membrane. RAS can be 
activated by multiple signaling pathways, some of which promote cell growth and 
survival. Binding to GTP activates RAS, leading to a conformational change in the 
protein. When RAS is in the “on” conformation, it has a high affinity for various effector 
proteins, allowing it to continue signal transduction pathways in the cell. 
In mammals, there are three RAS family members: HRAS, NRAS, and KRAS. 
Mutations that render the RAS proteins constitutively GTP-bound and active can induce 
cancer by continuously promoting cell growth. In humans, KRAS is the RAS family 
member that is most commonly mutated in cancers. One mechanism to elevate KRAS 
expression is by gene amplification. However, gene amplification cannot account for all 
KRAS driven tumors.  This suggests KRAS protein levels are elevated by unknown 
mechanisms during tumor progression. Though KRAS is the most frequently mutated RAS 
family member, it is an inherently weak oncogene due to usage of rare codons. 
Interestingly, each of the three RAS family proteins have a highly conserved amino acid 
sequence (greater than 90% identical) but a very different nucleotide sequence. KRAS has 
a large bias towards rare codons, while HRAS and NRAS use more common codons 
(Baines et al. 2011, Lampson et al. 2013). Recently, a study by the Counter and 
MacAlpine labs in our department found that replacing the rare codons in KRAS with 
common codons led to larger tumors in mice, even though changing the codons does not 
affect the actual amino acid sequence of the protein (Lampson et al. 2013). In a follow up 
paper, it was found that rare codons increase the likelihood of initiating tumorigenesis in 
vivo in mice, which would explain why KRAS, with its rare codons, is found so much 
more frequently in human cancers that HRAS or NRAS (Pershing et al. 2015). These two 
results indicate together that HRAS and NRAS likely induce senescence when they 
become oncogenic, which helps the organism avoid cancer. However, cells with 
oncogenic KRAS persist while avoiding senescence, which leads to a far higher rate of 
tumor formation when KRAS is mutated in animals.
In order to model RAS codon bias in Drosophila, we have created a system of 
transgenic flies with an easily visible phenotype that is comparable to the common HRAS 
and rare KRAS in mammals. Constitutively active Ras overexpression in the developing 
fly eye leads to excess cell proliferation, which results in a roughened appearance (Karim 
et al. 1996). Drosophila has only one version of the Ras gene (Ras1) that has a majority 
of common codons except for its C-terminus, which has a string of rare codons. 
Therefore, transgenic flies were created in which a constitutively active version of the 
Ras gene (RasV12) containing either all common codons, all rare codons, or unaltered 
codons was placed under control of a UAS promoter. These lines were crossed to a line 
with a Sevenless-Gal4 driver that drives expression of the Ras transgenes specifically in 
the developing eye. Flies with the Ras transgene that contained only common codons 
have a far more severe eye phenotype than those with the rare codon version. Western 
blots I have performed indicate this difference in phenotype correlates with a difference 
in Ras protein levels between the common and rare transgenic lines.
In order to determine genes that affect codon bias, we have conducted a 
deficiency screen on the entirety of the fly genome. I specifically contributed to a large 
part of the screen focused on the left arm of chromosome 2 (2L). In our screen, we 
examined flies expressing our altered Ras genes that are also heterozygous for each 
deficiency, thus presumably reducing the dose of each gene covered by 50%. Deficiencies 
that either suppress or enhance the rough eye phenotype of both the rare and common 
lines are likely general Ras modifiers. Deficiencies could also modify the rough eye 
phenotype of only the common Ras fly or only the rare Ras fly. Any novel modifier would 
be interesting, but we were specifically looking for deficiencies that only modify the 
common or the rare rough eye phenotype, as these deficiencies are more likely to contain 
genes that regulate codon-biased genes in particular.
Methods
1. Fly Stocks
The Bloomington Deficiency kit (Cook et al. 2012) was used in the initial 
deficiency screen. All fly stocks were from the Bloomington stock center unless indicated 
otherwise. Transgenic flies with UAS RNAi hairpin constructs were obtained from Vienna 
TRiP libraries ((Dietzl et al. 2007) to test candidate genes. The RpS21 mutant was 
obtained from the Bloomington stock center, stock#11339, genotype P{PZ}RpS2103575 
cn1/Cyo; ry506.
2. RasV12 Codon Bias constructs
The rare, common, and unaltered constructs were created using coding exons 
only. The common and rare sequences were generated using Kasuza Codon Usage 
Database (Nakamura 2007). The sequences were then physically generated by 
GENEART. These sequences were then cloned into the pDONR221 Gateway entry 
vector. The sequences were subsequently cloned into the pBID-UASC-FG destination 
vector (AddGene Plasmid #35201) (Wang et al. 2012). These vectors facilitate directed 
genomic insertion via PhiC31. attP40 was the landing site chosen (on chromosome 2). 
Injections were performed by Model System Injection (Durham, NC).
3. Immunoblotting
Protein samples were obtained by homogenizing 40 or 20 fly heads in Laemmli 
buffer and boiling for five minutes. The samples were separated by 12% SDS-PAGE and 
transferred to a nitrocellulose membrane for immunoblotting. Membranes were washed 
in TBST and blocked in 5% milk in TBST. FLAG tags in the sequence of the Ras 
transgenes allowed for visualization by a FLAG antibody - (1:500, Sigma, FLAG anti-
mouse M2, cat#F1804). Measurements from the FLAG were normalized to an α-tubulin 
loading control visualized by an α-tubulin antibody - (1:20,000, Sigma, anti-mouse, 
cat#T6199). Secondary antibodies were used at a concentration of 1:20,000 (LiCor, 
Donkey anti-Mouse, lot#C40520-04). The fluorescence signal was detected by a LI-COR 
Odyssey imager. Three replicates for each sample were used.
4. Deficiency Screen
For all chromosomes except the X, female virgins with the UAS-FLAG-RasV12rare 
or UAS-FLAG-RasV12common transgene balanced over Cyo were crossed to male 
deficiency/mutant/RNAi flies and raised in a 25ºC incubator. For the X chromosome, 
virgin deficiency females were crossed to male Ras transgene flies. After 18 to 21 days, 
all progeny were counted and scored for eye phenotype severity as described in the 
results.  Flies which received the Ras transgene but not the deficiency acted as a built in 
control to the experimental flies which received both the deficiency and Ras transgene. 
Eyes were scored as either mild, moderate, or severe.  From the resulting data, three 
separate severity scores were computed.  By comparing these scores between control and 
deficiency siblings, deficiencies were scored as suppressors, enhancers, or non-modifiers.  
Among the suppressors/enhancers, deficiencies were further scored as differential 
modifiers if a modification phenotype was found for only common or only rare 
transgenes.
Results
1. Modeling Ras codon bias in the Drosophila eye
Although Ras codon bias has been modeled successfully in mice, we set out to 
create a model in flies that could be more quickly and easily manipulated to elucidate the 
molecular mechanisms underlying Ras codon bias. However, we had to initially 
determine whether our model would mirror the phenotype seen in mice. Because 
Drosophila has only Ras gene, we needed to construct codon altered transgenes in order 
to understand whether codon bias has any impact on Ras in flies.
In order to model codon bias, three transgenes were constructed: UAS-FLAG-
RasV12common, which consists entirely of codons common in the fly genome, UAS-
FLAG-RasV12rare, which contains rare codons, and UAS-FLAG-RasV12nonaltered, which 
is the sequence of the endogenous fly Ras and serves as a control (Fig. 1A). These 
sequences all create the same protein, but have divergent nucleotide sequences (Table 1). 
The FLAG tag in the sequence allows for protein visualization when immunoblotting. 
Additionally, each of these transgenes is constitutively activated via the V12 mutation, 
which changes the glycine at position 12 to a valine, rendering Ras constitutively GTP 
bound. 
The UAS promoter sequence in each transgene allows for tissue specific gene 
expression. By placing these transgenes under the control of a Sevenless Gal4 construct, 
we were able to drive expression of Ras solely in Sevenless-expressing photoreceptors of 
the developing fly eye. Expression of these constitutively active Ras genes leads to the 
expected roughened eye phenotype in adult flies, which is known to be due to cellular 
overgrowth (Karim et al 1996). A range of roughened eye phenotypes occur, which we 
classified into three categories: mild, in which there is slight cell overgrowth, but no 
discoloration; moderate, in which there is significant overgrowth and discoloration of the 
eye; and severe, in which there is significant overgrowth and black necrotic spots (Fig. 
1B). To date, we have never found a phenotypically normal eye in flies expressing one of 
these transgenes.
A previous study in mice demonstrated that an oncogenic KRAS that has been 
modified to contain common codons produces larger tumors than does ectopically 
expressed endogenous KRAS, which contains rare codons (Lampson et al 2013). In 
agreement with this, we found that flies with eyes expressing UAS-FLAG-RasV12common 
have far more severe eye phenotype than flies expressing UAS-FLAG-RasV12rare (Fig. 
1C).
One explanation for the difference in eye phenotype severity between the rare and 
common Ras flies could be that the rare Ras flies have less Ras protein than do the 
common Ras flies. To test this, I assessed Ras protein levels in the UAS-FLAG-
RasV12common, UAS-FLAG-RasV12rare, and UAS-FLAG-RasV12nonaltered lines (Fig. 
1D). There was no significant difference between the nonaltered and common lines, 
which is not surprising because the endogenous version of Ras has a strong common 
codon bias: 57% of codons are common as opposed to only 17% being rare. However,  I 
found over a two-fold difference between the protein levels of both the rare and non 
altered lines and the common and rare lines (Fig. 1E), indicating that the difference in eye 
phenotype severity is likely due to a difference in protein accumulation.  This result 
agrees with the aforementioned study in mice, in which the researchers concluded that a 
difference in protein level was also responsible for the difference in tumor size they 
found between KRAS with rare codons and KRAS with common codons (Lampson et al 
2013). Thus, we established a model of Ras codon bias in Drosophila which matches 
findings that have been observed in a mammalian system. 
2. Deficiency screen for modifiers of the Ras codon bias phenotype
After successfully modeling Ras codon bias in the fly, we conducted a deficiency 
screen to search for modifiers of the codon biased Ras phenotype (Fig. 2). We specifically 
chose to do a deficiency screen because genetic screens are unbiased, genome-wide 
approaches to identifying genetic modifiers and have been successfully used to find 
modifiers in the Ras pathway (Karim et al 1996). Unlike other deficiency screens, in 
which deficiencies either enhance or suppress a single phenotype, we were interested in 
deficiencies that would only modify either our UAS-FLAG-RasV12rare or UAS-FLAG-
RasV12common transgenic flies, but not both. This would indicate that a deficiency was 
not modifying the phenotype of Ras in general, but was affecting it in a codon biased 
manner.
Out of 471 deficiency lines, we successfully identified and confirmed 26 
deficiencies that act as differential modifiers. These modifiers act in a range of ways, 
either enhancing or suppressing the UAS-FLAG-RasV12rare or UAS-FLAG-RasV12common 
phenotype (Fig 3B, Table 3). Additionally, we identified 107 deficiencies that act as 
enhancers and 60 that act as suppressors, confirming that our screen can identify general 
modifiers of the Ras protein (Fig 3A, Table 2). 
2.  Identification of Ribosomal Protein S21 as a codon-specific Ras modifier
After identifying a deficiency that acts as a differential modifier, the next goal is 
to identify which specific gene in the deficiency is causing the differential modifier 
phenotype. Because many of the potential candidate genes in regions of our differential 
modifier deficiencies are not well characterized, there are not mutants stocks available for 
a majority of the genes. Thus, I initially tested a wide range of mutants of candidate genes 
that were located in various deficiencies on chromosome 2L, instead of focusing on a 
specific deficiency. I crossed the available mutants to both the UAS-FLAG-RasV12rare and 
UAS-FLAG-RasV12common lines to determine if they reproduced the codon biased 
phenotype of the parental deficiency.
From this first pass, I identified a gene, Ribosomal Protein S21 (RpS21), which 
acted as a differential modifier in the same way as its parental deficiency: RpS2103575 
heterozygosity specifically enhances the phenotype of the UAS-FLAG-RasV12rare flies 
without modifying the phenotype of the UAS-FLAG-RasV12common flies (Fig. 4A). This 
gene is found in Df(2L)BSC692 (Stock 26544), which is located on chromosome 2L and 
contains 10 genes. This result has been repeated six times, confirming that RpS21 is likely 
the gene responsible for the phenotype of its parental deficiency. This is an important 
result, as it shows that our approaches can be successful for identifying genes that 
differentially modify our codon biased phenotype, which will help us more clearly 
understand the molecular mechanisms that underlie Ras codon bias.
To determine if RpS21 affects the rare transgene phenotype via a change in 
protein levels, which was likely due to it role in translation, I assessed protein levels of 
UAS-FLAG-RasV12common and UAS-FLAG-RasV12rare flies heterozygous for the RpS21 
mutant allele. In both replicates, no significant difference in Ras protein levels was found 
between the control and experimental flies of either the rare or common flies (Fig. 4B-D). 
Thus, RpS21 may regulate Ras codon bias in a manner independent of protein level 
control.
Discussion
In order to find a gene that affects codon bias, we wanted to create a fly model of 
Ras codon bias so that we could screen the entire genome quickly in an unbiased manner 
for genes that played a role in the underlying mechanisms of Ras codon bias. We have 
created transgenic versions of fly Ras that are 100% identical in amino acid sequence, but 
vary greatly with regards to their codons usage. As has been found in mammalian RAS 
through work done by the Counter lab (Lampson et al 2013), we see a significant 
decrease in Ras protein when driving expression of oncogenic Ras using a construct 
consisting of rare codons, compared to a construct with common codons. This decrease in 
protein levels is significant (p=0.038), and corresponds to a decrease in the severity of the 
eye phenotype of animals with the UAS-FLAG-RasV12rare transgene. These results 
indicate that we have successfully created a model of Ras codon bias in flies.
After screening the genome, we identified 26 separate deficiencies that 
differentially modify the codon biased phenotype. Instead of all modifying the phenotype 
in the same way, we see a broad range of changes, which suggests that there might be a 
large variety of these codon bias modifying genes that act in different ways. We have also 
identified a number of enhancers and suppressors of the Ras phenotype, indicating that 
our screen was successful in finding general Ras modifiers.
I narrowed one deficiency down to the gene for Deficiency(2L)BSC692, and 
identified Ribosomal Protein S21 (RpS21) as our first differential modifier gene. RpS21 is 
a protein in the small ribosomal subunit. Flies homozygous for a RpS21 deletion are 
viable, indicating that this protein is not intrinsically necessary for protein translation, and 
might function as more of an accessory protein (Torok et al. 1999). This leads to the 
hypothesis that RpS21 normally slows down processing of rare mRNAs at the ribosome 
due to more stable interactions with it than with the common mRNA; if RpS21 functions 
in this way, it would explain why we see a more severe eye phenotype in UAS-Flag-
RasV12rare flies heterozygous for the RpS21 mutant allele.
In our experiment, RpS2103575 heterozygosity increased the severity of the UAS-
FLAG-RasV12rare phenotype almost two-fold, while it did not alter the UAS-FLAG-
RasV12common phenotype. Initially, we suspected that RpS21 loss led to faster translation 
and accumulation of rare Ras protein, which would account for the increase in severity. 
However, two Western blots measuring Ras protein levels in RpS21 mutants and controls 
indicated no increase in protein between UAS-FLAG-RasV12rare flies heterozygous for 
the RpS21 mutant allele and control flies. Despite these results, we have not ruled out the 
possibility that loss of RpS21 works to increase UAS-FLAG-RasV12rare translational 
efficiency for two reasons: first, because both of the gels were overloaded with protein, 
making quantification difficult; second, it is possible that small changes of protein levels 
within a cell could have large impacts on the eye severity phenotype, and these small 
changes may not be able to be measured at the level of the Western blot in the way we are 
assaying it (with whole animal heads). If the latter is the case, we plan to do the 
experiments instead in Drosophila S2 cells, which may reduce some of the variability in 
assessing protein levels that we see in our whole animal model. Ideally, this would lead to 
a cleaner and more convincing experiment.
Moving forward, we hope to identify differential modifiers at the gene level for 
each deficiency found in the screen, as I did for RpS21. Given the range in phenotypes for 
the differential modifiers we have identified, it seems likely that codon biased modifying 
genes can act in a variety of ways to effect changes. We suspect that many will act via 
increasing or lessening the amount of protein produced, but it is very possible that some 
of these genes act in much less direct ways, potentially by altering cell fate or 
susceptibility of the cell to Ras. Identifying a novel mechanism that regulates only UAS-
FLAG-RasV12rare mRNA or protein product but not UAS-FLAG-RasV12common would be 
ideal, especially if it translated over to a mammalian system - if there was a pathway that 
only targeted KRAS (with its rare codons), we could potentially exploit the pathway in the 
treatment of cancer. However, if what we find is not translational or medically relevant, it 
could still prove important in furthering our limited knowledge of the biological effects 
of codon bias.
 Figure 1. Model of Ras Codon Bias in the Drosophila Eye. (A) Codon biased constructs. (B) Range of eye 
phenotypes observed in transgenic flies. (C) Severity score comparison of  UAS-FLAG-RasV12common and 
UAS-FLAG-RasV12rare transgenic flies. (D) Immunoblot showing reduced Ras protein levels in UAS-FLAG-
RasV12rare flies compared to UAS-FLAG-RasV12common flies. (E) Quantification of immunoblot in D 
normalized to α-tubulin (p=0.038).
  
Figure 2. Schematic of deficiency screen set up (adapted from Walker and Bernards, 2014).
Figure 3. (A) General modifiers found in deficiency screen out of 471 lines. (B) Breakdown of 
differential modifier phenotypes.
  
Figure 4. (A) Fold change in severity score of rare and common lines crossed to the mutant RpS21 allele and its 
parental deficiency, Df(2L)BSC692, compared to their respective controls. (B) Quantification of immunoblot in C, 
D normalized to α-tubulin. (C) Immunoblot of UAS-FLAG-RasV12common flies heterozygous for RpS21 mutant 
allele (experimental) and lacking the RpS21 mutant allele (control). (D) Immunoblot of UAS-FLAG-RasV12rare 
flies heterozygous for RpS21 mutant allele (experimental) and lacking the RpS21 mutant allele (control).
 Table 1. Nucleotide and Amino Acid Identity of Ras Transgenes
Table 2. Modifiers identified in deficiency screen.
Construct Protein Identity with 
Drosophila Ras





Chromosome Deficiencies Enhancers Suppressors Differential
X 93 30 (32.3%) 3 (3.2%) 6 (6.5%)
2L 99 28 (28.3%) 8 (8.1%) 8 (8.1%)
2R 92 34 (37.0%) 7 (7.6%) 4 (4.3%)
3L 77 6 (7.8%) 16 (20.8%) 5 (6.5%)
3R 103 9 (8.7%) 19 (18.4%) 3 (2.9%)
4 7 0 4 (57.1%) 0
Total 471 107 (22.7%) 57 (12.1%) 26 (5.5%)
Stock # Deficiency Chromosome Phenotype
7713 Df(1)Exel6239 X Enhances rare, not common
7714 Df(1)Exel6240 X Enhances rare, not common
25065 Df(1)BSC537 X Suppresses common, not rare
25697 Df(1)BSC622 X Suppresses common, not rare
26853 Df(1)BSC755 X Suppresses rare, not common
33829 Df(1)815-6 X Suppresses common, not rare
9615 Df(2L)BSC188 2L Enhances common, not rare
9642 Df(2L)BSC214 2L Enhances common, not rare
23663 Df(2L)BSC278 2L Enhances rare, not common
24114 Df(2L)ED1161 2L Enhances common, not rare
24958 Df(2L)BSC454 2L Enhances common, not rare
26542 Df(2L)BSC690 2L Enhances rare, not common
26544 Df(2L)BSC692 2L Enhances rare, not common
27353 Df(2L)781 2L Enhances rare, not common
7544 Df(2R)Exel6062 2R Suppresses common, not rare
7546 Df(2R)Exel6064 2R Suppresses common, not rare
23691 Df(2R)BSC308 2R Enhances common, not rare
30590 Df(2R)BSC885 2R Enhances common, not rare
3650 Df(3L)M21 3L Suppresses common, not rare
7588 Df(3L)Exel6109 3L Enhances common, not rare
8072 Df(3L)ED4486 3L Enhances common, not rare
8073 Df(3L)ED4543 3L Enhances common, not rare
24914 Df(3L)BSC410 3L Suppresses rare, not common
24909 Df(3R)BSC321 3R Enhances rare, not common
25001 Df(3R)BSC497 3R Suppresses rare, not common
30592 Df(3R)BSC887 3R Suppresses rare, not common
Table 3. Differential modifiers identified in deficiency screen.
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